Total reported value
$1.5B
Reporting period: 2026-03-31 · Number of holdings: 28
Caligan Partners LP disclosed 28 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.5B and a quarterly turnover rate of 53.9%.
Trim MLYS
-45.3% -$108.9M
Trim ABVX
+0.7% -$33.0M
Add RVMD
+46.6% $80.7M
Trim LQDA
0.0% $26.4M
Add PCVX
+20.9% $41.1M
Trim ADMA
+67.9% -$9.4M
Showing top 26 holdings (of 28 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 20.39% | -2.66% | — | |
| 2 | RVMD | Revolution Medicines INC | Stock-Healthcare | 12.18% | +3.76% | +46.56% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 10.83% | -5.29% | +0.69% | |
| 4 | PCVX | Vaxcyte INC | Stock-Other | 7.97% | +1.49% | +20.88% | |
| 5 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 5.39% | +1.33% | +26.71% | |
| 6 | MLYS | Mineralys Therapeutics INC | Stock-Other | 5.00% | -10.15% | -45.32% | |
| 7 | EXEL | Exelixis INC | Stock-Healthcare | 4.43% | -1.17% | — | |
| 8 | CGON | Cg Oncology INC | Stock-Other | 4.05% | +4.05% | NEW | |
| 9 | TNGX | Tango Therapeutics INC | Stock-Other | 3.35% | +0.63% | -35.42% | |
| 10 | TYRA | Tyra Biosciences INC | Stock-Other | 3.25% | +1.21% | +35.24% | |
| 11 | ADMA | Adma Biologics INC | Stock-Healthcare | 3.03% | -1.49% | +67.85% | |
| 12 | SYRE | Spyre Therapeutics INC | Stock-Other | 2.95% | +2.95% | NEW | |
| 13 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 2.30% | +2.30% | NEW | |
| 14 | VOR | Vor Biopharma INC | Stock-Other | 2.29% | +1.47% | +108.10% | |
| 15 | SABS | Sab Biotherapeutics INC | Stock-Other | 2.03% | +2.03% | NEW | |
| 16 | IRD | Opus Genetics INC | Stock-Other | 1.84% | +1.84% | NEW | |
| 17 | IVA | Inventiva SA - Adr | Stock-Other | 1.84% | +1.07% | +148.75% | |
| 18 | MBX | Mbx Biosciences INC | Stock-Other | 1.69% | +1.69% | NEW | |
| 19 | AVTX | Avalo Therapeutics INC | Stock-Other | 1.62% | +0.30% | +85.47% | |
| 20 | ANIK | Anika Therapeutics INC | Stock-Other | 1.38% | +0.24% | — | |
| 21 | MAZE | Maze Therapeutics INC | Stock-Other | 1.22% | -0.66% | +11.77% | |
| 22 | VRCA | Verrica Pharmaceuticals INC | Stock-Other | 0.33% | -0.30% | — | |
| 23 | FTH | Faeth Therapeutics INC | Stock-Other | 0.26% | +0.26% | NEW | |
| 24 | AGIO | Agios Pharmaceuticals INC | Stock-Other | 0.20% | — | — | |
| 25 | AURA | Aura Biosciences INC | Stock-Other | 0.10% | +0.10% | NEW | |
| 26 | XLO | Xilio Therapeutics INC | Stock-Other | 0.06% | +0.06% | NEW |
Performance for Q3 2026
+37.9%
Performance Last 4 Quarters
+134%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 28 | $1.5B | 54 | |
| 2025-12-31 | 24 | $1.2B | 73 | |
| 2025-09-30 | 18 | $763.5M | 97 | |
| 2025-06-30 | 17 | $520.2M | 0 | |
| 2025-03-31 | 16 | $479.2M | 0 | |
| 2024-12-31 | 14 | $394.9M | 0 | |
| 2024-09-30 | 12 | $315.5M | 0 | |
| 2024-06-30 | 13 | $428.0M | 0 | |
| 2024-03-31 | 12 | $378.3M | 0 | |
| 2023-12-31 | 11 | $296.5M | 0 | |
| 2023-09-30 | 13 | $217.8M | 0 | |
| 2023-06-30 | 13 | $177.8M | 0 | |
| 2023-03-31 | 11 | $143.4M | 0 | |
| 2022-12-31 | 11 | $120.2M | 0 |
Caligan Partners LP's most significant position changes for 2026-03-31: New buy: Cg Oncology INC (CGON); New buy: Spyre Therapeutics INC (SYRE); Sold out: Inhibrx Biosciences INC (INBX); New buy: Lb Pharmaceuticals INC (LBRX); New buy: Sab Biotherapeutics INC (SABS).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | +3.8% | +46.56% | Add |
| 2 | PCVX | Vaxcyte INC | +1.5% | +20.88% | Add |
| 3 | VOR | Vor Biopharma INC | +1.5% | +108.10% | Add |
| 4 | XENE | Xenon Pharmaceuticals INC | +1.3% | +26.71% | Add |
| 5 | TYRA | Tyra Biosciences INC | +1.2% | +35.24% | Add |
| 6 | IVA | Inventiva SA - Adr | +1.1% | +148.75% | Add |
| 7 | TNGX | Tango Therapeutics INC | +0.6% | -35.42% | Trim |
| 8 | AVTX | Avalo Therapeutics INC | +0.3% | +85.47% | Add |
| 9 | ANIK | Anika Therapeutics INC | +0.2% | — | Unchanged |
| 10 | AGIO | Agios Pharmaceuticals INC | — | — | Unchanged |
| 11 | VRCA | Verrica Pharmaceuticals INC | -0.3% | — | Unchanged |
| 12 | MAZE | Maze Therapeutics INC | -0.7% | +11.77% | Add |
| 13 | EXEL | Exelixis INC | -1.2% | — | Unchanged |
| 14 | ADMA | Adma Biologics INC | -1.5% | +67.85% | Add |
| 15 | LQDA | Liquidia CORP | -2.7% | — | Unchanged |
| 16 | ABVX | Abivax Sa-adr | -5.3% | +0.69% | Add |
| 17 | MLYS | Mineralys Therapeutics INC | -10.2% | -45.32% | Trim |
| 18 | CGON | Cg Oncology INC | — | NEW | New buy |
| 19 | SYRE | Spyre Therapeutics INC | — | NEW | New buy |
| 20 | INBX | Inhibrx Biosciences INC | — | EXIT | Sold out |
| 21 | LBRX | Lb Pharmaceuticals INC | — | NEW | New buy |
| 22 | SABS | Sab Biotherapeutics INC | — | NEW | New buy |
| 23 | IRD | Opus Genetics INC | — | NEW | New buy |
| 24 | MBX | Mbx Biosciences INC | — | NEW | New buy |
| 25 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 26 | FTH | Faeth Therapeutics INC | — | NEW | New buy |
| 27 | SPRB | Spruce Biosciences INC | — | EXIT | Sold out |
| 28 | AURA | Aura Biosciences INC | — | NEW | New buy |
| 29 | XLO | Xilio Therapeutics INC | — | NEW | New buy |
| 30 | ELDN | Eledon Pharmaceuticals INC | — | EXIT | Sold out |